NCT06264531 (BevacizuMAV) is a Phase 2, PHASE3 clinical trial of Bevacizumab in Cerebral AV Malformation, sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

Who is sponsoring NCT06264531?

NCT06264531 is sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

What drugs are being tested in NCT06264531?

Interventions in NCT06264531: Bevacizumab, Placebo.

What condition does NCT06264531 study?

NCT06264531 studies Cerebral AV Malformation.

Is NCT06264531 still recruiting?

NCT06264531 is currently recruiting now. Last updated 22 January 2026.

Last reviewed 2026-01-22 · How we verify

NCT06264531: BevacizuMAV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations

Recruiting now Phase 2, PHASE3 Last updated 22 January 2026

What this trial tests

Phase 2, PHASE3 trial testing Bevacizumab in Cerebral AV Malformation in 54 participants. Currently enrolling.

Timeline

16 January 2026

Primary endpoint
15 January 2028

15 January 2029

Quick facts

Lead sponsor	Fondation Ophtalmologique Adolphe de Rothschild
Phase	Phase 2, PHASE3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	54
Start date	16 January 2026
Primary completion	15 January 2028
Estimated completion	15 January 2029
Sites	1 location across France

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Placebo

Conditions studied

Cerebral AV Malformation — all drugs for Cerebral AV Malformation →

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild — full company profile →

Who can join

18 and older, any sex, with Cerebral AV Malformation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Brain arteriovenous malformations (AVMs) are responsible for hemorrhagic strokes, particularly in children and young adults. They can also be responsible for chronic neurological disorders: motor or sensory deficits, disturbances of higher functions, epilepsy or disabling headaches. The management of brain AVMs is complex and requires a multidisciplinary approach in an expert center. Available therapies include endovascular embolization, neurosurgical resection and/or radiosurgery. These procedures carry a risk of neurological complications, and are reserved for small AVMs located at a distance from highly functional cerebral structures. To date, no drug therapy is recommended if interventional treatment is not possible. Several studies on resected brain AVM tissue have demonstrated that these malformations are the site of significant evolutionary inflammatory and neo-angiogenesis processes. Other studies have specifically shown that VEGF (vascular endothelial growth factor) levels are increased in AVMs. More recently, a pre-clinical study showed that anti-angiogenic treatment with Bevacizumab reduced vascular proliferation within AVMs in mice. Finally, a Phase II clinical trial in patients with Rendu-Osler disease (a genetic vascular disorder characterized by recurrent epistaxis, cutaneous telangiectasia and the presence of visceral AVMs) showed a clinical benefit of IV Bevacizumab on the symptomatology of these vascular malformations, with a reduction in the risk of hemorrhage and the extent of hepatic arteriovenous shunts. A randomized Phase III trial is currently underway (NCT03227263) to assess the efficacy of IV Bevacizumab in Rendu-Osler disease. The aim of our study is to assess the efficacy of IV Bevacizumab on the disabling symptoms associated with symptomatic brain AVMs.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Pathophysiology in Brain Arteriovenous Malformations: Focus on Endothelial Dysfunctions and Endothelial-to-Mesenchymal Transition.
Jeong JY, Bafor AE, Freeman BH, Chen PR, et al · · 2024 · cited 6× · PMID 39200259 · DOI 10.3390/biomedicines12081795
Extracranial arteriovenous malformations: towards etiology-based therapeutic management.
Coulie J, Seront E, Vikkula M, Boon LM. · · 2025 · cited 5× · PMID 40091828 · DOI 10.1172/jci172837
Advances in sporadic brain arteriovenous malformations: Novel genetic insights, innovative animal models and emerging therapeutic approaches.
Ueki Y, Naylor RM, Ghozy SA, Thirupathi K, et al · · 2025 · cited 2× · PMID 39948029 · DOI 10.1177/0271678x251319913
Targeted medical therapies for vascular anomalies.
Borst A. · · 2024 · cited 1× · PMID 39644074 · DOI 10.1182/hematology.2024000599
Advances in the Genetics and Molecular Biology of Brain Arteriovenous Malformations.
Tsuchiya T, Miyawaki S, Ono H, Hongo H, et al · · 2026 · PMID 41999461 · DOI 10.1007/s12975-026-01436-7
Vascular malformations: from genetics to therapeutics.
Morin G, Galasso I, Canaud G. · · 2026 · PMID 41272322 · DOI 10.1038/s44321-025-00344-x

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other Fondation Ophtalmologique Adolphe de Rothschild trials

Trials by the same sponsor.

NCT04701619 — Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE) · NA · not yet recruiting
NCT04763161 — Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Cas · not yet recruiting
NCT06895044 — Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study · recruiting
NCT06644196 — Creation of a Database of Images of the Eye With the Holographic Doppler Laser · recruiting
NCT05847699 — Radiohistological Correlation of Thrombohemorrhagic Remodeling in the Acute Phase of Ischemic Stroke Managed by Decompre · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06264531 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondation Ophtalmologique Adolphe de Rothschild
Last refreshed: 22 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06264531.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing